Development of Vitamin D as a Therapy for Breast Cancer - Phase II
This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Vitamin D
Phase: Phase 2
Ages Eligible For Study:
- Women undergoing core needle biopsy for a breast abnormality suspicious for breast cancer. Women who have undergone a core needle biopsy demonstrating breast cancer who have not yet had any further therapy are also eligible so long as their core needle biopsy is available for analysis. - No prior therapy for breast cancer. - Age 18 years or older. - Ability to understand and the willingness to sign a written informed consent document. - Signed informed consent